Aileron Therapeutics Reports Leadership and Compensation Changes
Ticker: RNTX · Form: 8-K · Filed: Mar 29, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics Inc (RNTX) |
| Form Type | 8-K |
| Filed Date | Mar 29, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, sec-filing
TL;DR
Aileron Therapeutics filed an 8-K on 3/25/24 reporting director changes and executive compensation updates.
AI Summary
On March 25, 2024, Aileron Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or financial adjustments that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate underlying issues or strategic realignments that warrant closer investor scrutiny.
Key Numbers
- 001-38130 — SEC File Number (Identifies the company's filing with the SEC.)
- 13-4196017 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- March 25, 2024 (date) — Date of earliest event reported
- 001-38130 (company) — SEC File Number
- 738 Main Street #398 Waltham, MA 02451 (company) — Principal Executive Offices Address
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific names and details of these changes are not provided in the excerpt.
What are the key aspects of the reported compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers', suggesting updates or details regarding executive pay, but specific details are not in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 25, 2024.
What is Aileron Therapeutics, Inc.'s principal executive office address?
The principal executive office is located at 738 Main Street #398, Waltham, MA 02451.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 973 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2024-03-29 08:03:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d800276d8k.htm (8-K) — 27KB
- 0001193125-24-081562.txt ( ) — 144KB
- alrn-20240325.xsd (EX-101.SCH) — 3KB
- alrn-20240325_lab.xml (EX-101.LAB) — 17KB
- alrn-20240325_pre.xml (EX-101.PRE) — 11KB
- d800276d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: March 29, 2024 By: /s/ Brian Windsor, Ph.D. Brian Windsor, Ph.D. President and Chief Executive Officer